Gan & Lee Pharmaceuticals. (603087.SH) has announced that its self-developed GLR2037 tablet has commenced a Phase I clinical trial in China, with the first participant recently receiving the initial dose. GLR2037 is a Class 1 chemical new drug, specifically an androgen receptor protein degradation targeting chimera (ARPROTAC), independently developed by the company. The trial is designed to evaluate the drug's potential for treating advanced prostate cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments